显然，白酒行业目前仍处于深度调整期，库存积压、价格倒挂、经销商退出等现象在近两年似乎愈演愈 烈，白酒消费市场遇冷，市场复苏态势较弱等情况成为常态，几乎所有的白酒企业都面临新的挑战，此 时考验的便是企业穿越周期的能力，比起盲目激进，立足长远、拥抱长期主义才是头部酒企应有的担 当。 面对行业变局，作为头部酒企的洋河选择主动慢下节奏，积极调整经营策略，稳固提升产品品质，全面 推动营销转型。据悉，洋河在去年主动减少白酒产量，帮助经销商释放库存，减轻压力；同时优化产品 结构，创新文化表达，通过产品升级在高端及中高端市场实现新突破。 持续升级焕新产品 4月28日晚，洋河股份发布2024年报。2024年实现营业收入288.76亿元，归属于上市公司股东的净利润 66.73亿元。公司拟以现有总股本逾15亿股为基数，向全体股东每10股派发现金红利23.17元（含税）， 派发现金红利共计34.9亿元（含税）。 这样一份成绩单在引发讨论背后，也让更多人看到白酒行业当下的困境与企业的积极求变。从目前披露 2024年报的白酒上市公司来看，多家企业出现业绩下滑，其中不乏净利暴跌近一倍的企业，头部酒企也 普遍出现业绩增速放缓的情况。 构建完 ...

Core Viewpoint - The company reported its Q1 2025 performance, showing stable revenue growth but a slight decline in net profit, indicating a mixed financial outlook for the period [1]. Financial Performance - In Q1 2025, the company achieved revenue of 12.713 billion yuan, a year-on-year increase of 4.87%, while the net profit attributable to shareholders was 459 million yuan, a slight decline of 0.10% [1]. - The company's net profit excluding non-recurring items was 446 million yuan, down 2.57% year-on-year, aligning with expectations [1]. - The parent company reported a revenue of 5.94 billion yuan in Q1 2025, representing a year-on-year growth of 16.3%, and a net profit of 340 million yuan, up 6.8% year-on-year [2]. Cost Management - The sales expense ratio decreased to 1.2%, down 0.5 percentage points year-on-year, attributed to cost optimization, while the management expense ratio remained stable at 0.8% [2]. - Industrial investment income for Q1 2025 was 103 million yuan, reflecting a year-on-year increase of 0.9% [2]. Research and Development - The company is accelerating its R&D efforts, particularly in the field of narcotic drugs, and has optimized its product structure for 2024 [2]. - The company has received registration approvals for several new products, including a first-class psychotropic raw material, and is collaborating with research institutions to enhance its research capabilities [2]. Marketing Strategy - The company is transforming its marketing approach to empower its national pharmaceutical distribution business, focusing on enhancing bidding, channel development, and data services [3]. - A diverse marketing model has been established, covering various fields such as oral products, blood products, and second-class psychotropic drugs [3]. Profit Forecast and Valuation - The company maintains its net profit forecasts for 2025 and 2026 at 2.131 billion yuan and 2.270 billion yuan, respectively, both reflecting a year-on-year growth of 6.5% [4]. - The current stock price corresponds to a price-to-earnings ratio of 10.4 times for 2025 and 9.8 times for 2026, with a target price of 38.0 yuan, indicating a potential upside of 29.3% [4].